Biotech · Public company · Newark, CA, US
Protagonist Therapeutics, Inc
Ticker PTGX · SEC CIK 0001377121
Track this companyFree. Adds Protagonist Therapeutics, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials92 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline7
- Open-label rusfertidePhase 3 · Polycythemia VeraClinicalTrials.gov · fetched Nov 12, 2026
- RusfertidePhase 3 · Polycythemia VeraClinicalTrials.gov · fetched Nov 12, 2026
- PN-943Phase 2 · Ulcerative Colitis Chronic ModerateClinicalTrials.gov · fetched Nov 12, 2026
- PTG-100Phase 2 · Ulcerative ColitisClinicalTrials.gov · fetched Nov 12, 2026
- PTG-300Phase 2 · Hereditary HemochromatosisClinicalTrials.gov · fetched Nov 12, 2026
- PTG-300Phase 2 · Polycythemia VeraClinicalTrials.gov · fetched Nov 12, 2026
- PTG-300Phase 2 · β-thalassemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia VeraPHASE3 · ACTIVE_NOT_RECRUITING · started Jan 22, 2024ClinicalTrials.gov NCT06033586 · fetched Nov 12, 2026
- A Study of Rusfertide in Adults With Polycythemia Vera (PV)PHASE3 · ACTIVE_NOT_RECRUITING · started Apr 11, 2022ClinicalTrials.gov NCT05210790 · fetched Nov 12, 2026
- PTG-100 for Patients With Celiac DiseasePHASE1 · COMPLETED · started Feb 26, 2021ClinicalTrials.gov NCT04524221 · fetched Nov 12, 2026
- PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)PHASE2 · COMPLETED · started Aug 5, 2020ClinicalTrials.gov NCT04504383 · fetched Nov 12, 2026
- PTG-300 in Subjects With Hereditary HemochromatosisPHASE2 · COMPLETED · started Mar 19, 2020ClinicalTrials.gov NCT04202965 · fetched Nov 12, 2026
- Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)PHASE2 · COMPLETED · started Oct 1, 2019ClinicalTrials.gov NCT04057040 · fetched Nov 12, 2026
- Safety Study for Beta Thalassemia Subjects on PTG-300PHASE2 · COMPLETED · started May 10, 2019ClinicalTrials.gov NCT04054921 · fetched Nov 12, 2026
- Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic AnemiaPHASE2 · COMPLETED · started Dec 19, 2018ClinicalTrials.gov NCT03802201 · fetched Nov 12, 2026
- Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative ColitisPHASE2 · TERMINATED · started Dec 1, 2016ClinicalTrials.gov NCT02895100 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 18, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jan 12, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 6, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 6, 2025 · fetched Nov 12, 2026